Developing better drugs by detecting how they reach their targets
July 8, 2013
Called CETSA (Cellular Thermal Shift Assay), the method could improve the development of new improved drug substances.
Most drugs operate by binding to one or more proteins and affecting their function, which creates two common bottlenecks in the development of drugs: identifying the right target proteins and designing drug molecules able to efficiently seek out and bind to them.
No method has been available for directly measuring the efficiency of the drug molecules to locate and bind to its target protein.
“We have shown that [CETSA] works on a wide variety of target proteins and allows us to directly measure whether the drug molecules reach their targets in cells and animal models,” says lead investigator Professor Pär Nordlund of the Department of Medical Biochemistry and Biophysics.
“We believe that CETSA will eventually help to improve the efficiency of many drugs and contribute to better drug molecules and more successful treatments.”
Control stage and diagnostic tool
The lack of methods to directly measure the binding of a drug to its target protein has caused a degree of uncertainty in many phases of drug development. In some cases, where drug candidates have not lived up to expectations in clinical trials on humans, it has transpired that the drug molecules have failed to bind to the right protein. The group behind the study believes that CETSA will be an important control stage and a complement to other methods.
In the present study, the researchers also examined processes that can lead to drug resistance in cells. The team believes that by virtue of its ability to determine whether existing drugs are suitable for individual patients, the method is of potential value to the practice of individualized treatment.
“We believe that the method can provide an important diagnostic tool in the treatment of cancer, for example, as CETSA can, in principle, enable us to determine which drug is most effective at targeting the proteins in the tumor,” says Daniel Martinez Molina at the Department of Medical Biochemistry and Biophysics, who leads a team in the project aiming at establishing CETSA for patient studies. “This also makes it possible for clinicians to ascertain at an early stage of treatment whether the tumor has developed a certain kind of resistance and which type of therapy could then be more suitable for the patient.”
The evaluation of CETSA has been conducted in collaboration with Yihai Cao’s research group at the Department of Microbiology,Tumor and Cell Biology at Karolinska Institute, Pelago Bioscience AB and Nanyang Technological University in Singapore. The project was financed by grants from the Swedish Research Council, the Swedish Cancer Society, and the European Research Council (ERC).